PAK1 and acute myeloid leukemia: These data indicate that, on average, patients with low PAK1 activity lived 5 times longer than those with high activation of this kinase and give weight to the notion that PAK1 is a suitable target for the treatment of AML cases that respond poorly to current treatments.